By Lewis Krauskopf
NEW YORK (Reuters) – Sluggish U.S. biotech shares could require a wave of deal-making or exciting clinical trial results if the sector wants to join the stock market’s party after lagging Wall Street’s broad advance this year.
More certainty…
